Stifel Financial Corp Has $574,000 Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Stifel Financial Corp cut its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 8.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,705 shares of the biopharmaceutical company’s stock after selling 263 shares during the quarter. Stifel Financial Corp’s holdings in Madrigal Pharmaceuticals were worth $574,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in MDGL. RTW Investments LP boosted its stake in shares of Madrigal Pharmaceuticals by 4.1% during the 3rd quarter. RTW Investments LP now owns 1,993,687 shares of the biopharmaceutical company’s stock worth $423,100,000 after acquiring an additional 77,825 shares in the last quarter. Cinctive Capital Management LP acquired a new stake in Madrigal Pharmaceuticals in the 3rd quarter worth approximately $1,077,000. Erste Asset Management GmbH bought a new stake in Madrigal Pharmaceuticals during the third quarter worth approximately $49,749,000. Paulson & CO. Inc. grew its holdings in Madrigal Pharmaceuticals by 10.4% during the third quarter. Paulson & CO. Inc. now owns 2,042,000 shares of the biopharmaceutical company’s stock valued at $433,353,000 after purchasing an additional 192,000 shares during the last quarter. Finally, Braidwell LP bought a new position in shares of Madrigal Pharmaceuticals in the third quarter valued at approximately $39,010,000. 98.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MDGL has been the subject of several recent analyst reports. B. Riley upped their price objective on shares of Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. StockNews.com raised Madrigal Pharmaceuticals to a “sell” rating in a research report on Saturday, October 12th. UBS Group boosted their price objective on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and issued a $390.00 target price on shares of Madrigal Pharmaceuticals in a report on Tuesday, October 22nd. Finally, Oppenheimer cut their price target on Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $347.33.

Madrigal Pharmaceuticals Stock Performance

NASDAQ:MDGL opened at $314.04 on Friday. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. The firm has a 50-day moving average price of $296.96 and a 200 day moving average price of $268.92. The firm has a market capitalization of $6.85 billion, a PE ratio of -12.52 and a beta of -0.42. Madrigal Pharmaceuticals, Inc. has a 12-month low of $168.25 and a 12-month high of $368.29.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($4.92) EPS for the quarter, beating the consensus estimate of ($6.94) by $2.02. The company had revenue of $62.18 million during the quarter, compared to analyst estimates of $34.60 million. During the same period in the prior year, the firm earned ($5.34) EPS. Research analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.77 earnings per share for the current fiscal year.

Insider Transactions at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, Director Richard S. Levy sold 5,000 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, November 1st. The stock was sold at an average price of $300.94, for a total value of $1,504,700.00. Following the completion of the transaction, the director now owns 11,012 shares in the company, valued at approximately $3,313,951.28. The trade was a 31.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Fred B. Craves sold 3,600 shares of the stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $315.31, for a total value of $1,135,116.00. Following the sale, the director now owns 11,000 shares in the company, valued at $3,468,410. The trade was a 24.66 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,000 shares of company stock valued at $3,830,836. 22.80% of the stock is owned by insiders.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.